{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T15:21:12Z","timestamp":1768317672311,"version":"3.49.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T00:00:00Z","timestamp":1520467200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/about_us\/legal\/notices"}],"funder":[{"DOI":"10.13039\/501100003323","name":"Agence Nationale de Recherches sur le Sida et les Hepatites Virales","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003323","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1093\/jac\/dky062","type":"journal-article","created":{"date-parts":[[2018,2,16]],"date-time":"2018-02-16T07:08:55Z","timestamp":1518764935000},"page":"1665-1671","source":"Crossref","is-referenced-by-count":16,"title":["High virological suppression regardless of the genotypic susceptibility score after switching to a dolutegravir-based regimen: week 48 results in an observational cohort"],"prefix":"10.1093","volume":"73","author":[{"given":"Charlotte","family":"Charpentier","sequence":"first","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Peytavin","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Pharmacologie-Toxicologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh P","family":"L\u00ea","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Pharmacologie-Toxicologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9ronique","family":"Joly","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service de Maladies Infectieuses et Tropicales, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ornella","family":"Cabras","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, 75018 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marine","family":"Perrier","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Le Gac","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, 75018 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bao","family":"Phung","sequence":"additional","affiliation":[{"name":"AP-HP, H\u00f4pital Bichat-Claude Bernard, Service de Maladies Infectieuses et Tropicales, 75018 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service de Maladies Infectieuses et Tropicales, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diane","family":"Descamps","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Laboratoire de Virologie, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Landman","sequence":"additional","affiliation":[{"name":"IAME, UMR 1137, INSERM, Universit\u00e9 Paris Diderot, Sorbonne Paris Cit\u00e9, AP-HP, Service de Maladies Infectieuses et Tropicales, H\u00f4pital Bichat, AP-HP, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,3,8]]},"reference":[{"key":"key\n\t\t\t\t20180518035615_dky062-B1","doi-asserted-by":"crossref","first-page":"295","DOI":"10.3851\/IMP3166","article-title":"Dolutegravir\/abacavir\/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study","volume":"22","author":"Trottier","year":"2017","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180518035615_dky062-B2","first-page":"844","article-title":"Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals","volume":"72","author":"Negredo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035615_dky062-B3","author":"Llibre"},{"key":"key\n\t\t\t\t20180518035615_dky062-B4","author":"Joly"},{"key":"key\n\t\t\t\t20180518035615_dky062-B5","author":"Reynes"},{"key":"key\n\t\t\t\t20180518035615_dky062-B6","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1093\/jac\/dkw186","article-title":"Dolutegravir as monotherapy in HIV-1-infected individuals with suppressed HIV viraemia","volume":"71","author":"Katlama","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035615_dky062-B7","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3851\/IMP3082","article-title":"Dolutegravir monotherapy as treatment de-escalation in HIV-infected adults with virological control: doluMono cohort results","volume":"22","author":"Oldenbuettel","year":"2017","journal-title":"Antivir Ther"},{"key":"key\n\t\t\t\t20180518035615_dky062-B8","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/QAD.0b013e3283427de3","article-title":"Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy\/ml","volume":"25","author":"Ha\u00efm-Boukobza","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180518035615_dky062-B9","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1002\/jmv.21405","article-title":"Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation","volume":"81","author":"Bonora","year":"2009","journal-title":"J Med Virol"},{"key":"key\n\t\t\t\t20180518035615_dky062-B10","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/bmc.865","article-title":"Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry","volume":"21","author":"Jung","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"key\n\t\t\t\t20180518035615_dky062-B11","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1097\/QAD.0b013e32834a1dd9","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults","volume":"25","author":"Min","year":"2011","journal-title":"AIDS"},{"key":"key\n\t\t\t\t20180518035615_dky062-B12","author":"Song"},{"key":"key\n\t\t\t\t20180518035615_dky062-B13","author":"L\u00ea"},{"key":"key\n\t\t\t\t20180518035615_dky062-B14","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1093\/jac\/dkx018","article-title":"Switch as maintenance to elvitegravir\/cobicistat\/emtricitabine\/tenofovir disoproxil fumarate: week 48 results in a clinical cohort","volume":"72","author":"Perrier","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20180518035615_dky062-B15","doi-asserted-by":"crossref","first-page":"e0134430.","DOI":"10.1371\/journal.pone.0134430","article-title":"Use of PCR signal and therapeutic drug monitoring in a switch cohort study to tenofovir\/emtricitabine\/rilpivirine: a W96 follow-up","volume":"10","author":"Charpentier","year":"2015","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20180518035615_dky062-B16","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1128\/AAC.37.10.2231","article-title":"High-level resistance to (\u2212) enantiomeric 2\u2032-deoxy-3\u2032-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase","volume":"37","author":"Boucher","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20180518035615_dky062-B17","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1002\/j.1460-2075.1996.tb00777.x","article-title":"Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme","volume":"15","author":"Back","year":"1996","journal-title":"EMBO J"},{"key":"key\n\t\t\t\t20180518035615_dky062-B18","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/S2352-3018(17)30069-3","article-title":"Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286\/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial","volume":"4","author":"Ciaffi","year":"2017","journal-title":"Lancet HIV"},{"key":"key\n\t\t\t\t20180518035615_dky062-B19","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1093\/jac\/dkx233","article-title":"HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir+lamivudine in the maintenance DOLULAM pilot study","volume":"72","author":"Charpentier","year":"2017","journal-title":"J Antimicrob Chemother"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/73\/6\/1665\/24804813\/dky062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T22:58:10Z","timestamp":1570748290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/73\/6\/1665\/4924890"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,8]]},"references-count":19,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,3,8]]},"published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dky062","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,6]]},"published":{"date-parts":[[2018,3,8]]}}}